M DEUCRAVACITINIB (is an active metabolite) | DEUCRAVACITINIB | ATC L04AF07
IMMUNOSUPPRESSANTS IMMUNOMODULATING AGENTS TYROSINE KINASE 2 (TYK2) ALLOSTERIC INHIBITOR TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS BMT-153261 ACCOUNTS FOR APPROXIMATELY 20 PERCENT OF THE SYSTEMIC EXPOSURE | - | Cmax 12.1 NANOMOLAR | TYROSINE KINASE 2 (TYK2) | tyrosine kinase 2 (TYK2) UNIPROT P29597 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |